We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cortexin (polypeptide cortex bioregulator)
A low-molecular-weight polypeptide complex extracted from cattle/pig brain cortex, registered and very widely prescribed as a neuroprotective 'nootropic' medicine in Russia and CIS countries — so it has real (if mostly Russian-language and methodologically weak) human studies. Cortexin is given by intramuscular injection for stroke, cognitive impairment, epilepsy and pediatric neurology, with claimed neuroprotective and antioxidant effects mediated via glutamatergic/GABAergic activity. Animal work shows it crosses the blood-brain barrier and binds AMPA/kainate/GABA receptors. But the honest picture is sobering: in a rigorous double-blind rodent stroke comparison, cortexin was no better than saline (only cerebrolysin beat placebo), and Russian human trials are typically small, unblinded, single-center, and often show cortexin underperforming comparator drugs. It is NOT FDA-approved or a dietary supplement. Treat the neuroprotection claims as weakly evidenced.
Prescription medication — not a dietary supplement
Cortexin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Cortexin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1999–2026 with a typical study size of 110 participants.
Based on 17 studies · 1 meta-analysis · 11 RCTs · 110 total participants
Confidence
Moderate confidenceBy outcome
Scores a low Emerging 2 because, despite a plausible receptor mechanism, its human evidence is small unblinded Russian trials, it failed to beat saline in a rigorous animal study, and an independent meta-analysis found too few trials to pool.
12 rigorous studies
12 randomized trials · 0 meta-analyses · 0 systematic reviews
Our evidence rating for Cortexin is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
Cortexin is a complex of low-molecular-weight (water-soluble) polypeptides and amino acids extracted by acetic-acid hydrolysis from the cerebral cortex of cattle (and pig) brain.
It is registered and extremely widely used as a neuroprotective/nootropic injectable medicine across Russia and the CIS, prescribed for ischemic stroke, traumatic brain injury, cognitive impairment, encephalopathy, epilepsy, and a broad range of pediatric neurological conditions.
Because it is a registered drug there, cortexin has a substantial — but methodologically weak and overwhelmingly Russian-language — clinical literature, which distinguishes it from grey-market research peptides with no human data.
Mechanistically, the best preclinical work comes from a 2021 PLoS ONE rodent study showing that radiolabeled cortexin crosses the blood-brain barrier (reaching 6-8% of whole-blood concentration) and that cortexin binds with high-to-moderate affinity to AMPA, kainate, mGluR1, mGluR5 and GABA-A receptors in vitro, suggesting its in-vivo effects in ischemia models may be glutamatergic/GABAergic; in that study cortexin reduced infarct necrosis, supported the antioxidant system, and improved neurological recovery in rats — comparable to cerebrolysin and better than actovegin.
However, the most rigorous, independent test is unflattering: in a prospective, randomized, double-blind, placebo-controlled rodent embolic-stroke study run at Henry Ford Hospital comparing four brain-hydrolysate preparations, cortexin produced functional outcomes and lesion volumes no different from saline, while only cerebrolysin significantly improved neurological recovery.
The Russian human trials are mostly small (typically 30-90 patients per arm), unblinded, single-center, and use surrogate or clinician-rated endpoints (NIHSS, MMSE, MoCA, Barthel index): some report faster regression of neurological and cognitive deficits when cortexin is added to standard stroke care or combined with mexidol, and a biomarker study reported falling NR2-peptide levels after a cortexin course — but in a head-to-head against Cellex, cortexin was the less effective agent on NIHSS and MMSE.
The honest assessment: cortexin is a real, registered, heavily-prescribed neuroprotective drug with a plausible receptor-level mechanism and demonstrable blood-brain-barrier penetration, but its clinical evidence is dominated by small, unblinded, single-country studies, it has failed to separate from placebo in the one rigorous independent animal comparison, it frequently underperforms comparator drugs, and an independent systematic review/meta-analysis of animal-derived nootropics found only a single eligible cortexin trial (80 patients) — too few to pool — and judged the supporting evidence weak and the effects probably below clinical relevance.
Western regulators have NOT approved it; it is neither an FDA-approved medicine nor a lawful dietary supplement; long-term safety beyond short injection courses is not well characterized; and it should be used only under a clinician in jurisdictions where it is registered.
In-vitro binding assays show cortexin binds with high-to-moderate affinity to AMPA, kainate, mGluR1, mGluR5 and GABA-A receptors. Its neuroprotective effects in animal ischemia models are attributed to this glutamatergic/GABAergic action — though the precise downstream mechanism in humans is not established.
Radiolabeled cortexin crossed the blood-brain barrier in mice, reaching 6-8% of whole-blood concentration in brain tissue — supporting the plausibility of a central effect after injection, a meaningful hurdle many peptide claims fail.
In rodent acute/chronic ischemia models, cortexin reduced the size of necrotic brain tissue, improved antioxidant-system function, and limited neurodegenerative changes. The proposed route from receptor activity to tissue protection — demonstrated in animals.
How Cortexin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — safety in pregnancy and lactation is not established.
Cortexin is widely used in pediatric neurology in Russia/CIS, but that use rests on weak evidence; any pediatric use must be specialist-directed, never self-administered.
Avoid unregulated sources — identity, purity and sterility are not guaranteed (and the source tissue is animal brain); a registered pharmaceutical product under clinical care is the only defensible route.
Cortexin is frequently combined with other neuroprotectives (e.g. mexidol) in Russian practice; net effects of such combinations are not rigorously studied and should be clinician-directed.
Cortexin binds AMPA/kainate/GABA receptors in vitro; theoretical additive effects with other glutamatergic/GABAergic drugs have not been studied and warrant clinical caution.
Tip: Administer per clinical protocol; cortexin is reported to be generally well tolerated in short courses.
Tip: Stop and seek care if an allergic reaction occurs.
Tip: Long-term safety outside studied short courses is poorly characterized; do not self-administer chronically.
The current evidence for Cortexin is insufficient to assign an evidence score, based on 15 indexed studies, including 1 meta-analysis. A low-molecular-weight polypeptide complex extracted from cattle/pig brain cortex, registered and very widely prescribed as a neuroprotective 'nootropic' medicine in Russia and CIS countries — so it has real (if mostly Russian-language and methodologically weak) human studies. Cortexin is given by intramuscular injection for stroke, cognitive impairment, epilepsy and pediatric neurology, with claimed neuroprotective and antioxidant effects mediated via glutamatergic/GABAergic activity. Animal work shows it crosses the blood-brain barrier and binds AMPA/kainate/GABA receptors. But the honest picture is sobering: in a rigorous double-blind rodent stroke comparison, cortexin was no better than saline (only cerebrolysin beat placebo), and Russian human trials are typically small, unblinded, single-center, and often show cortexin underperforming comparator drugs. It is NOT FDA-approved or a dietary supplement. Treat the neuroprotection claims as weakly evidenced. Representative study: PMID 36324709.
The commonly studied dose of Cortexin is Cortexin is a registered prescription neuroprotective drug in Russia/CIS, NOT a dietary supplement — this library does not provide a self-administration protocol. Where registered, it is given by intramuscular injection (commonly 10 mg/day, or 20 mg/day for adults, as a 10-day course), but any use must be directed by a clinician in a jurisdiction where it is approved.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Cortexin — consistent daily use matters more than the time of day. Cortexin is injected intramuscularly and dosed as a fixed daily course; timing follows the clinical protocol rather than food or circadian considerations.
Cortexin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-related reactions, hypersensitivity to brain-derived peptide material, unknown long-term effects. Use caution if any of these apply to you: Not an FDA-approved drug or a regulated dietary supplement — registered as a prescription neuroprotective drug only in Russia/CIS; use only under a clinician; Known hypersensitivity to cortexin or to bovine/porcine brain-derived peptide preparations; Pregnancy and breastfeeding (not established as safe).
Creatine
Likely helpsIncreases phosphocreatine stores for faster ATP regeneration, boosting strength, power output, and cognitive function under stress.
Omega-3
Probably helpsEssential fatty acids critical for brain health, mood regulation, and reducing inflammation throughout the body.
Acetyl-L-Carnitine
Likely helpsAcetylated carnitine that crosses the blood-brain barrier to fuel mitochondrial energy and donate acetyl groups for acetylcholine synthesis.
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 17 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research